⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2024

Supplementary Data 1 from First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial

Tao Li Ying Dong Yongzhong Wei Shoufeng Wang Yunxia Liu Jia Chen Wenhua Xiong Nong Lin Xin Huang Meng Liu Xiaobo Yan Zhaoming Ye Binghao Li

View at Publisher

Ask AI

Bookmark

Share

Abstract

Supplementary File 1. Inclusion and exclusion criteria.Supplementary Table S1. Representativeness of trial patients.Supplementary Table S2. Summary of adverse events.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Li et al. (2024) studied this question.

synapsesocial.com/papers/68e56226e2b3180350efef02 https://doi.org/10.1158/1078-0432.27142227

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Data from First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial2024
2First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial2024 · 26 citations
3Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II TrialCohort Study · 2022 · 20 citations
4First-Line Tyrosine Kinase Inhibitors in Soft-Tissue Sarcomas: A Role for Anlotinib?2024
5Table S4 from Results of an Open-label, Phase 1a/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced or Metastatic Soft Tissue Sarcoma2024

More related papers

Table S4 from Results of an Open-label, Phase 1a/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced or Metastatic Soft Tissue Sarcoma2024
Supplementary Figure S1 from A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas2025
Supplementary Figure S3 from A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas2025